| abstract |
The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis. In one aspect, there is provided an anthranilamide pyridiurea compound of the general formula (I): (see formula I) or an isomer, diastereoisomer, enantiomer, tautomer or salt thereof. |